Kx Advisors ’s Post

The first results from the platform trial MND-SMART, led by UK DRI Director Prof Siddharthan Chandran, Prof Suvankar Pal, and the Euan MacDonald Centre for Motor Neuron Disease Research at the University of Edinburgh, have been reported in the Lancet Neurology. The trial aims to significantly speed up delivery of new treatments for motor neuron disease (MND). Memantine and trazodone were tested & found not to be effective compared with placebo - but the innovative trial design has halved the time taken to test these treatments. Prof Siddharthan Chandran said: “There is an urgent need for new treatments for people affected by MND. Through MND-SMART, we have halved the time taken to conclusively test two drugs, showing the trial is doing exactly what it set out to. Momentum is gathering, and I am hopeful that this approach will, in time, deliver effective, disease-modifying treatments for people with MND.” Read the full story ⬇️

Amyloid and Tau models recapitulate pathological processes found in patients with Alzheimer’s Disease, including protein aggregation, neuroinflammation, neurodegeneration, and cognitive impairments. The key to understanding a therapeutic compound’s effect on amyloid-beta pathology-induced neuroinflammation, is to use robust and reliable models that consistently show progressive plaque pathology, such as the APP/PS1 (ARTE10) model. View example histopathological data here: https://lnkd.in/eKhpC6nX To view other models, browse through InnoSer's portfolio here: https://lnkd.in/ejQFTpA6 👉 Do you have specific questions relating to our Alzheimer's disease models? Our InnoSer neurology team is exhibiting (booth #22) at the upcoming #ADPD2024 conference and will be happy to answer any of your questions relating to Alzheimer's or other neurodegenerative disease models.

Last week, here on LinkedIn, you met Juan M. Valdez Capuccino, Ph.D. as he walked the halls of the annual Alzheimer's Association International Conference in Philly as one of BGB Group's distinguished neurology experts. Today, in partnership with Exene Anderson, PhD and our Kx Advisors colleagues Chris Waybill, Adriana González-Caballero, and Chloe Weiser, Juan is digging a bit deeper into one of the topics that came up - blood biomarkers in Alzheimer's Disease diagnosis. Did you know the average predicted wait time between clinical diagnosis and treatment of AD is 18.6 months? We invite you to learn more about the different types of BBMs and how they may evolve patient diagnosis of AD and the treatment journey. Read more about this topic in the link below: https://go.bgbx.ai/BBBM

I am very happy to have contributed and to be associated as a co-author in this collaborative work published in Neurology aimed at improving our understanding of primary cerebral angeitis and cerebral amyloid angiopathy-related inflammation, two very severe and unfortunately too poorly understood diseases. The fight against rare diseases is a global challenge that transcends borders and disciplines. International collaborations are therefore crucial, bringing together diverse expertise, resources, and perspectives that can lead to groundbreaking discoveries and innovative treatments. By working together, researchers from around the world can pool their knowledge and skills to accelerate the pace of scientific advancements. It is through such collaborations that we can hope to make significant strides in the diagnosis, treatment, and ultimately, the eradication of rare diseases. Together, we can turn the tide against these formidable foes and bring hope to countless patients and their families worldwide. Link: https://lnkd.in/eqfgwEhB

Top Studies in Neurology From 2023: New Drugs in Alzheimer's: Monoclonal antibodies against beta amyloid for the treatment of early Alzheimer's disease. - For two monoclonal antibodies, lecanemab and donanemab, there was efficacy in slowing the disease progression. - But in practical terms, these two treatments pose significant problems . First ; For diagnosis, you need PET-CT. Second ; The therapy has to be done via IV regularly, every 2 weeks or every 4 weeks. Along side number of side effects , which need MRI control , and the high cost of the treatment . - We have, at present, no infrastructure for treating these patients. We also have a number of monoclonal antibodies that were not effective. _Hans-Christoph Diener, MD,PhD_ the medical faculty of University Duisburg-Essen in Germany

Generalized myasthenia gravis is a chronic autoimmune disorder without a cure. A recent study by Zai Lab showed favorable results with Efgartigimod. Approximately 70% of patients transitioned to a mild disease state, with 39% achieving minimal symptom expression. These improvements are significant for patients and caregivers alike. #Qiming #QimingPortfolio #healthcare #ZaiLab #Clinical #TranslationalNerology #Efgartigimod #gMg #MyastheniaGravis #Argenx #medtech #biotech #Antibody

Zai Lab (NASDAQ: ZLAB, SEHK: 9688) has announced a study led by Professors Sushan Luo and Chongbo Zhao from Huashan Hospital, Fudan University, published in the Annals of Clinical and Translational Neurology. This research represents the first multi-center, real-world cohort study in China evaluating Efgartigimod for the treatment of generalized myasthenia gravis (gMG). Under an exclusive licensing agreement with argenx, Zai Lab is developing and commercializing Efgartigimod in Greater China to address significant unmet needs in autoimmune conditions. Key findings from the study include: - 97% of patients experienced clinically meaningful improvement within an average of 1.3±0.7 weeks. - Efgartigimod demonstrated efficacy across various antibody types and disease states, including MuSK antibody-positive, seronegative, acute exacerbation, and myasthenic crisis patients. - Approximately 70% of patients transitioned to a mild disease state, and 39% achieved minimal symptom expression after 12 weeks of follow-up. - The average daily dose of corticosteroids decreased from 28.3mg at baseline to 15.7mg over 12 weeks. #HealthcareInnovation #RareDiseases #ClinicalResearch #AutoimmuneDiseases #Neurology #Efgartigimod #QimingPortfolio #QimingHealthcare

Every five minutes, someone in the world is diagnosed with Multiple Sclerosis. But Professor Massimo Filippi, head of the Neurology Unit, of the Neurophysiology service and of the Neurorehabilitation Unit of the San Raffaele Hospital, states that a more precise and earlier diagnosis is becoming increasingly accessible. Until a couple of years ago, Multiple Sclerosis (MS) was diagnosed when no other diagnosis would fit, while now it can be recognized as early as 3 months after the first clinical episode. Early treatment, even with currently available drugs, significantly alters the progression of common disabilities. Moreover, according to Professor Gianvito Martino, Scientific Director of the San Rafaelle Hospital, the research on MS is also progressing towards understanding the mechanisms behind its progression. Over the past twenty years, therapies have been developed to target and prevent the damage. Now efforts are focused on regenerating tissue damaged in the later stages of the disease. Emerging studies and new therapies, including pharmacological treatments, cell transplantation, and gene modification, are showing promising results. With approximately 2.9 million people affected by MS globally, GSD is dedicated to supporting them in every way possible. You too can support our researchers by donating your5xmille to the research labs of the San Raffaele Hospital. There is no cure without research. #GruppoSanDonato #GSDHealthMag #ScienceBased #WorldMSday #WorldMultipleSclerosisDay

Excited to share our new paper in Frontiers in Neurology which was published today. The paper, titled “Spectris™ Treatment Preserves Corpus Callosum Structure in Alzheimer’s Disease,” highlights the potential of Cognito’s Spectris™ as a disease-modifying candidate for #Alzheimer’s disease (AD). 🧠🧠 This is the first study to report on the ability of Spectris to preserve the corpus callosum in patients with mild to moderate Alzheimer’s disease. The corpus callosum is responsible for information transfer between the brain's hemispheres and plays a crucial role in maintaining #cognitive function. “The results highlight that preserving the structural integrity of the brain’s communication pathways could potentially slow cognitive decline and improve daily functioning,” said Ralph Kern, M.D., MHSc, Chief Medical Officer at Cognito Therapeutics. “This study supports Spectris as a potential disease-modifying therapy in Alzheimer’s, providing a different treatment modality beyond traditional drug-based approaches. Read the full release: https://lnkd.in/eEEhHdPy

Early and accurate diagnosis is paramount for autoimmune neurology disorders. Learn how our phenotype-specific testing approach effectively diagnoses and guides treatment for these patients. https://bit.ly/3AwZVyC